GlassScriptPhysician profile
Jun Dong Kim
NPI 1336411610
$1,664.01
in general payments reported to CMS, 2019-2025
31 companies · $79.42 in 2025
The $79.42 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $81.87 · 2021: $642 · 2022: $451 · 2023: $148 · 2024: $80.54 · 2025: $79.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $374.71 | 2021-2022 | |
| Abbvie INC. | $361.84 | 2019-2025 | |
| Amgen INC. | $88.78 | 2020-2023 | Evenity, Prolia |
| Lundbeck LLC | $80.88 | 2021 | |
| Amarin Pharma, INC. | $71.40 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $56.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.29 | 2019-2021 | |
| Organon LLC | $47.37 | 2022-2025 | Nexplanon |
| Sunovion Pharmaceuticals INC. | $47.31 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $45.63 | 2021 | |
| Indivior INC. | $36.12 | 2022-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $34.31 | 2021 | |
| Exeltis, USA INC. | $30.91 | 2021-2024 | Slynd |
| Axsome Therapeutics, INC. | $30.56 | 2023 | Auvelity |
| Corium, LLC | $26.13 | 2023 | Adlarity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $25.19 | 2022 | |
| Duchesnay USA Incorporated | $24.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.00 | 2022 | |
| Sumitomo Pharma America, INC. | $22.22 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $19.71 | 2022 | |
| Alvogen INC | $19.54 | 2025 | Teriparatide |
| Alkermes, INC. | $17.89 | 2022 | |
| Cequr Corporation | $17.43 | 2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2019 | |
| Convatec INC. | $15.74 | 2022 | |
| Merck Sharp & Dohme LLC | $14.69 | 2019 | |
| Novo Nordisk INC | $14.46 | 2023 | Wegovy |
| Eisai INC. | $14.00 | 2021 | |
| Astellas Pharma US INC | $13.18 | 2023 | Veozah |
| Roche Diagnostics Corporation | $11.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.